Form 10-K
BIOTIME INC filed this Form 10-K on 03/15/2018
Document Outline
Entire Document (7729 KB)
Subdocument 1 - 10-K
Page 1 - UNITED STATES
Page 2 - BioTime, Inc.
Page 3 - PART I
Page 4 - Deconsolidation of OncoCyte Corporation Effective February 17, 2017
Page 5 - HyStem
Page 6 - cell/drug delivery
Page 7 - Renevia
Page 8 - Products Enhancements
Page 9 - PureStem
Page 10 - N/A
Page 11 - OpRegen
Page 12 - OpRegen
Page 13 - Renevia
Page 14 - PureStem
Page 15 - N/A
Page 16 - DetermaVu
Page 17 - N/A
Page 18 - HyStem
Page 19 - N/A
Page 20 - N/A
Page 21 - OpRegen
Page 22 - Hextend
Page 23 - Premvia
Page 24 - in vitro
Page 25 - HyStem
Page 26 - PureStem
Page 27 - N/A
Page 28 - Renevia
Page 29 - OpRegen
Page 30 - N/A
Page 31 - de novo
Page 32 - N/A
Page 33 - By Geographic Area
Page 34 - OpRegen
Page 35 - Hextend
Page 36 - Risks Related to Our Business Operations and Capital Requirements
Page 37 - We will need to issue additional equity or debt securities in order to raise additional capital need
Page 38 - Our business could be adversely affected if we lose the services of the key personnel upon whom we d
Page 39 - If we do not receive regulatory approvals we will not be permitted to sell our therapeutic and medic
Page 40 - There is a risk that OncoCyte s planned diagnostic tests could become subject to FDA regulation
Page 41 - The ACA and future changes to that law may adversely affect our business.
Page 42 - Even if we receive approval for our products, we may be subject to extensive regulatory obligations
Page 43 - The commercial success of any of our current or future product candidates will depend upon the degre
Page 44 - If the market opportunities for our product candidates are smaller than we believe they are, we may
Page 45 - Our reliance on third parties to manufacture products, including Renevia , will subject us to risks
Page 46 - Any cell-based products that receive regulatory approval may be difficult and expensive to manufactu
Page 47 - Risks Related to our Intellectual Property
Page 48 - There is no certainty that our pending or future patent applications will result in the issuance of
Page 49 - We may become dependent on possible future collaborations to develop and commercialize many of our p
Page 50 - Risks Related to Our Affiliates
Page 51 - Changes in healthcare laws and policies may have a material adverse effect on OncoCyte s financial c
Page 52 - Private health insurance company policies may deny coverage or limit the amount they will reimburse
Page 53 - Our net income or loss will be impacted by changes in the market value of Asterias and OncoCyte comm
Page 54 - If we or our subsidiaries issue additional common shares or preferred shares, investors in our commo
Page 55 - C
Page 56 - PART II
Page 57 - Dividend Policy
Page 58 - Performance Measurement Comparison
Page 59 - BIOTIME, INC. AND SUBSIDIARIES
Page 60 - N/A
Page 61 - The following Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 62 - Equity method accounting for Asterias and OncoCyte, at fair value
Page 63 - Income taxes
Page 64 - Results of Operations
Page 65 - Research and development expenses
Page 66 - General and administrative expenses
Page 67 - Gain on sale of assets
Page 68 - Other income and expenses, net
Page 69 - Operating Expenses
Page 70 - N/A
Page 71 - General and administrative expenses
Page 72 - Other income and expenses, net
Page 73 - Liquidity and Capital Resources
Page 74 - Cash used in investing activities
Page 75 - Foreign Currency Exchange Risk
Page 76 - Report of Independent Registered Public Accounting Firm
Page 77 - Report of Independent Registered Public Accounting Firm
Page 78 - BIOTIME, INC. AND SUBSIDIARIES
Page 79 - BIOTIME, INC. AND SUBSIDIARIES
Page 80 - BIOTIME, INC. AND SUBSIDIARIES
Page 81 - BIOTIME, INC. AND SUBSIDIARIES
Page 82 - BIOTIME, INC. AND SUBSIDIARIES
Page 83 - N/A
Page 84 - BIOTIME, INC.
Page 85 - Principles of consolidation
Page 86 - 2. Summary of Significant Accounting Policies
Page 87 - Concentrations of credit risk
Page 88 - Property, plant and equipment, net
Page 89 - Transactions with Noncontrolling Interests of Subsidiaries
Page 90 - Stock-based compensation
Page 91 - Adoption of ASU 2016-09
Page 92 - 3. Deconsolidation of OncoCyte and Asterias
Page 93 - 4. Equity Method of Accounting for Common Stock of OncoCyte, at Fair Value
Page 94 - 5. Equity Method of Accounting for Common Stock of Asterias, at Fair Value
Page 95 - 6. Property, Plant and Equipment, Net
Page 96 - 8. Accounts Payable and Accrued Liabilities
Page 97 - Shared Facilities and Service Agreements with Affiliates
Page 98 - Other related party transactions
Page 99 - N/A
Page 100 - BioTime Warrants
Page 101 - Transactions with Noncontrolling Interests of AgeX Therapeutics, Inc.
Page 102 - Assumption of Liabilities:
Page 103 - N/A
Page 104 - General Option Information
Page 105 - 12. Commitments and Contingencies
Page 106 - Annual Rent Expense and Future Minimum Lease Payments
Page 107 - Royalty obligations and license fees
Page 108 - 13. Income Taxes
Page 109 - N/A
Page 110 - Other Income Tax Matters
Page 111 - Major Sources of Revenues
Page 112 - 16. Selected Quarterly Financial Information (UNAUDITED, in thousands, except per share data)
Page 113 - Evaluation of Disclosure Controls and Procedures
Page 114 - PART III
Page 115 - PART IV
Page 116 - N/A
Page 117 - N/A
Page 118 - N/A
Page 119 - SIGNATURES
Page 120 - N/A
Subdocument 2 - EX-10.38 - Material contracts
Page 1 - N/A
Page 2 - IN WITNESS WHEREOF, the Parties have duly executed this Amendment:
Page 3 - N/A
Page 4 - APPENDIX C DEVELOPMENT PLAN
Page 5 - October 24, 2017
Page 6 - N/A
Page 7 - N/A
Page 8 - Part II Hadasit IP
Page 9 - N/A
Page 10 - Part IV OCS Funded
Page 11 - N/A
Subdocument 3 - EX-21.1 - Subsidiaries of the registrant
Page 1 - Exhibit 21.1
Page 2 - N/A
Subdocument 4 - EX-23.1 - Consents of experts and counsel
Page 1 - EXHIBIT 23.1
Page 2 - N/A
Subdocument 5 - EX-23.2 - Consents of experts and counsel
Page 1 - Exhibit 23.2
Page 2 - N/A
Subdocument 6 - EX-31 - Certifications required under Section 302 of the Sarbanes-Oxley Act of 2002
Page 1 - Exhibit 31
Page 2 - Exhibit 31
Page 3 - Exhibit 31
Page 4 - N/A
Subdocument 7 - EX-32 - Certifications required under Section 906 of the Sarbanes-Oxley Act of 2002
Page 1 - Exhibit 32
Page 2 - N/A
Subdocument 8 - EX-99.1 - Exhibits not specifically designated by another number and by investment companies
Page 1 - Exhibit 99.1
Page 2 - ASTERIAS BIOTHERAPEUTICS, INC.
Page 3 - ASTERIAS BIOTHERAPEUTICS, INC.
Page 4 - ASTERIAS BIOTHERAPEUTICS, INC.
Page 5 - ASTERIAS BIOTHERAPEUTICS, INC.
Page 6 - ASTERIAS BIOTHERAPEUTICS, INC.
Page 7 - ASTERIAS BIOTHERAPEUTICS, INC.
Page 8 - 2. Summary of Significant Accounting Policies
Page 9 - Property, plant and equipment
Page 10 - Stock-based compensation
Page 11 - Basic and diluted net loss per share
Page 12 - Leases (Topic 842),
Page 13 - 3. Balance Sheet Components
Page 14 - 5. Intangible assets, net
Page 15 - Warrants classified as a liability
Page 16 - Warrants Outstanding in 2017, 2016 and 2015
Page 17 - Stock Options
Page 18 - Restricted Stock and Restricted Stock Units
Page 19 - Stock-Based Compensation Expense
Page 20 - 8. Commitments and Contingencies
Page 21 - Litigation General
Page 22 - 10. Income Taxes
Page 23 - N/A
Page 24 - 11. Segment Information
Page 25 - Distinguishing Liabilities from Equity SEC Materials
Page 26 - Telomerase Sublicense from Geron
Page 27 - Transactions Between Entities Under Common Control
Page 28 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer